Articles tagged with Tumor Growth
Researchers highlight key phagocytosis checkpoints and 'do not eat me' signals as potential therapeutic targets for novel immunotherapies. The editorial summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
Researchers propose a new approach to understanding cancer evolution, acknowledging the importance of environmental influences and epigenetic changes. By refining the clonal evolution model, they aim to develop more effective cancer therapies that consider the full complexity of cancer cell evolution.
A glitch in protein synthesis, known as stop codon readthrough, may affect tumour growth and cancer cell proliferation. The study found that preventing this process can lead to increased degradation of target proteins and a delayed cell cycle, resulting in slower tumour growth.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
A common skin fungus, Malassezia globosa, may invade deep tissues and cause tumor growth in breast cancer, according to a new study published in mBio. The researchers found that M. globosa colonizes in breast fat pads leading to tumor growth, suggesting a potential link between fungal colonization and cancer progression.
A new study reveals that the menstrual cycle plays a role in spreading mutant cells within mammary tissue, leading to large fields prone to tumor formation. Researchers observed that the growth and removal of extra milk ducts during the menstrual cycle can contribute to this process.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
Researchers create superhydrophobic array device (SHArD) mimicking the lotus leaf surface structure, enabling high-throughput generation of three-dimensional nanoscale tumor models. This platform helps study metastasis and primary tumors, shedding light on cancer progression.
Researchers found that targeting and silencing ERBB2 gene expression significantly increases chances of stopping tumor growth in mice with a PTEN mutation. This breakthrough may lead to alternative treatment options for endometrial cancer patients, reducing the risk of fertility issues associated with standard treatments.
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
Researchers discuss how PROM2 is a predictive biomarker of distant metastases and shorter survival among patients with stage III melanomas. They also demonstrate that runaway metastasis is closely linked to PROM2 overexpression, through increased epithelial-to-mesenchymal transition marker expression and ferroptosis resistance.
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
A new clinical algorithm developed at the University of Gothenburg can accurately identify highly aggressive forms of basal cell carcinoma. The algorithm uses a combination of clinical and dermoscopic images to distinguish between low-risk and high-risk tumors, allowing for more effective treatment and better patient outcomes.
Researchers analyzed collision-type mixed ductal-lobular breast cancers and found that IDC and ILC regions had distinct gene expression profiles. The study reveals tremendous variation within this already highly variable disease, highlighting the need for personalized treatments.
Researchers discovered that OTX2 interacts with splicing factors to control alternative splicing in genes fueling medulloblastoma development. Disturbing the PPHLN1 gene splicing with an anti-PPHLN1 drug reduces tumor growth, opening possibilities for improved treatments.
Researchers at Tufts University have identified the immune cells driving cardiac inflammation in cancer patients taking doxorubicin, a commonly used chemotherapy drug. Blocking these cells could potentially prevent cardiac damage and make treatment safer for patients.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Patients with mantle cell lymphoma are more vulnerable to other diseases and infections due to intensive chemotherapy and a weakened immune system. A large-scale national study found that MCL patients had twice as many infections as reference subjects, with common causes including influenza and urinary tract infections.
Researchers found that bowel cancer cells can regulate their growth using genetic on-off switches, allowing them to maximize survival chances. The study also showed that DNA repair genes can be repeatedly created and repaired, acting as 'genetic switches' to control tumour growth or put the brakes back on.
The special issue explores challenges and opportunities in managing synthetic genomics risks, introducing a common global baseline for nucleic acid synthesis screening. Review articles provide insights into enhancing gene synthesis security and biosecurity practices of synthetic DNA providers.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Researchers at Linköping University and the Medical University of Graz have developed a new cancer treatment using an iontronic pump to deliver continuous, low-dose chemotherapy directly to brain tumors. This approach significantly reduces tumor growth by bypassing the blood-brain barrier, a common obstacle to effective treatment.
Researchers discovered a new way to effectively treat melanoma using nutrients to reactivate suppressed metabolic pathways in cancer cells. The innovative treatment, involving tyrosine nanomicelles, showed promising results in mice and lab-derived human cells, inhibiting tumour growth and reducing glycolysis.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
A recent study from the Women's Health Initiative found that both obesity and metabolic syndrome increase breast cancer risk, but in distinct ways for different subtypes. The research highlights the importance of controlling waist circumference and metabolic conditions to reduce breast cancer risk.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
Researchers identified protein JUN as a potential therapeutic option to slow tumor growth in prostate cancer, contradicting previous findings that linked high JUN levels to increased tumor growth. The study showed that JUN slows tumor progression and improves immune response, providing a new starting point for therapy development.
Scientists discover Epstein-Barr virus alters gene regulation in nasopharyngeal cancer cells, leading to rapid tumour growth. The study offers new insights into the link between EBV and NPC, shedding light on intricate processes underlying disease progression.
A study has shown that a potassium ion channel located in mitochondria rewires metabolism in breast cancer cells, promoting tumor growth. The channel, BKCa, is linked to the Warburg effect, a metabolic hallmark of cancer, by causing increased lactate secretion and hydrogen peroxide levels.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
A stepped-care model integrating palliative care at key points in patients' cancer trajectories shows reduced palliative care visits without compromising quality of life. The approach enables more efficient delivery of early palliative care, enhancing patient-reported outcomes.
A new surgical platform using mass spectrometry identifies key gene mutations in brain cancer, including IDH mutations, during surgery. This allows for rapid diagnosis, prognosis, and tumor resection to improve patient outcomes.
A breakthrough discovery by Nara Institute of Science and Technology researchers identifies EPHA2 as a critical surface protein for preserving stem cell potency. This finding holds promise for safer regenerative medicine by reducing the risk of tumorigenesis, paving the way for organ repair and treatment of degenerative conditions.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Scientists at Sanford Burnham Prebys and Vanderbilt University have identified phosphatidylinositol-5-phosphate 4-kinases (PI5P4Ks) as a key regulator of the hippo pathway, which is dysregulated in cancer. The study suggests that targeting PI5P4Ks may lead to new treatments for cancers with abnormal hippo signaling.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Researchers found that middle fossa craniotomy significantly improved hearing preservation and quality of life for patients after removing an acoustic neuroma. The study showed excellent facial nerve outcomes in 94% of patients, while 68% preserved their hearing.
Researchers at Ben-Gurion University have discovered a molecular mechanism that enables cancer cells to survive under glucose starvation. By targeting this pathway, they aim to develop a molecule that can block the survival of tumor cells while leaving healthy cells unaffected.
Adult carriers of BAP1 tumor predisposition syndrome show a high incidence of onychopapillomas, a benign nail tumor. This finding suggests using these skin abnormalities to identify family members and patients with cancers associated with the syndrome.
Researchers have developed a new method to detect malignant melanoma using a microneedle patch that measures tyrosinase enzyme levels in the skin. This non-invasive technique has the potential to provide faster and more reliable results compared to traditional biopsies.
The Academic Payvider model enhances value-based care by fostering improved coordination, reduced insurance hassles, and increased staff attention. This joint approach between payers and providers aims to drive complex care down through innovative reimbursement structures.
Researchers found that UTIs can provoke structural changes in breast tissue in mice, which are reversible once the infections are resolved. The study suggests a possible link between UTIs and abnormal breast cell growth, highlighting the importance of considering everyday occurrences on women's well-being.
The study, published in Cell Stem Cell, improves the growth of nephron progenitor cells (NPCs) using a chemical cocktail, enabling sustained growth in a simple 2-dimensional format. The breakthrough has potential for advancing kidney research and discovering new treatments.
Researchers found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer. Mice given a diet rich in vitamin D had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
A study by researchers at Washington University School of Medicine has found that a drug used to treat epilepsy can prevent brain tumor formation and growth in mice with neurofibromatosis type 1 (NF1). The drug, lamotrigine, was shown to be effective at lower doses than those used for epilepsy, and its effects were lasting. The finding...
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Scientists at the University of California San Diego have identified a biochemical pathway that continually surveils mitosis timing and eliminates potentially problematic cells. The 'stopwatch' mechanism uses protein p53 to track cell division time, labeling sequentially delayed divisions as risky.
A team of researchers from Kyoto University has developed a microfluidic co-culture vasculature chip that mimics the microenvironment of alveolar soft part sarcoma (ASPS), a rare cancer. The chip enables scientists to study cell-to-cell interactions and angiogenic mechanisms, which may lead to new strategies for treating ASPS patients.
Scientists from UC3M and Johns Hopkins University have developed a computational model that simulates the invasion process of cancer cells based on the characteristics of surrounding tissue and cell junctions. The model allows for predicting tumor evolution in patients by analyzing mechanical properties of the microenvironment.
Researchers have identified a crucial interface in a mutated protein that drives lung cancer growth, which could act as a target for more effective treatments. The study used advanced laser imaging techniques to provide unprecedented details of the protein's structure and interactions.
A new study has discovered that Streptococcus anginosus bacteria play a significant role in causing stomach cancer. The research showed that S. anginosus infection led to gastric inflammation, cell damage, and the growth of stomach cancer cells, doubling tumour size and weight in some cases.